AbbVie’s Phase 3 Study on Upadacitinib for Alopecia Areata: Key Insights for Investors

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.

AbbVie is conducting a Phase 3 study titled A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Alopecia Areata and at Least 25% Scalp Hair Loss. The study aims to assess the safety, effectiveness, and tolerability of Upadacitinib in Japanese participants with severe alopecia areata, a condition where the immune system attacks hair follicles, causing hair loss.

The study tests Upadacitinib, an oral tablet, to treat alopecia areata. Participants receive either Upadacitinib or a placebo daily, with the possibility of re-randomization during the study.

This interventional study is randomized and follows a parallel assignment model with double masking. Its primary purpose is treatment-focused, ensuring unbiased results by keeping both participants and investigators unaware of the treatment assignments.

The study began on June 19, 2025, with its primary completion and estimated completion dates yet to be determined. The latest update was submitted on August 13, 2025, indicating ongoing recruitment.

This study could impact AbbVie’s stock performance positively if successful, as it expands the drug’s application to alopecia areata, potentially increasing market share. Investors should watch for developments, considering the competitive landscape in the pharmaceutical industry.

The study is ongoing, with further details available on the ClinicalTrials portal.